FIELD: medicine; pharmaceutics.
SUBSTANCE: invention relates to the field of medicine and pharmaceutics, namely to a method for the treatment of a neurodegenerative disease selected from amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease in a human, including daily oral or gastric administration of 10-250 ml of a liquid pharmaceutical composition for providing 30-300 mg of edaravon and 0.4-4 mg of edaravon per kg of the body weight, wherein the specified liquid pharmaceutical composition is a single-phase aqueous solution of non-complex 3-methyl-1-phenyl-2-pyrazoline-5-one (edaravon) and contains at least 75 wt.% of water and 0.2-9 mg/ml of edaravon.
EFFECT: invention provides for high oral bioavailability of edaravon.
16 cl, 5 tbl, 2 ex
